Centre Hospitalier Universitaire De Rennes
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
Clinical research at Centre Hospitalier Universitaire De Rennes includes work in infectious diseases focused on Cutibacterium spp. prosthetic joint infection. The trials are designed to assess whether a treatment approach can improve safety and effectiveness for patients with this challenging joint infection.
- Studying the role of rifampicin in managing prosthetic joint infection
- Evaluating treatment safety alongside infection control
This area reflects a practical effort to strengthen infection treatment and support better outcomes in patients with device-related bacterial infections.
Eye Diseases
The site also conducts research in ophthalmology, with trials centered on non-infectious uveitis affecting the intermediate, posterior, and pan-uveal regions. These studies aim to compare treatment options and improve control of inflammation in patients who depend on steroids.
- Comparing a targeted therapy with standard care for steroid-dependent uveitis
- Improving treatment choices for active inflammatory eye disease
This research is aimed at finding more effective ways to preserve vision and reduce long-term disease burden.
Immune System Diseases
In the field of immune-mediated diseases, investigators at this hospital are studying uveitis as an inflammatory disorder with immune system involvement. The research focuses on whether different therapies can better control disease activity and reduce reliance on steroids.
- Assessing immune-directed treatment strategies for inflammatory eye disease
- Seeking better control of steroid-dependent disease activity
The work highlights interest in improving care for patients with persistent inflammation through more tailored treatment approaches.
Neoplasms
Oncology research at Centre Hospitalier Universitaire De Rennes includes studies in standard risk ALK-positive anaplastic large cell lymphoma, a childhood and adolescent cancer. The trial aims to determine whether a simpler treatment approach can still achieve strong disease control.
- Evaluating treatment effectiveness in pediatric and adolescent lymphoma
- Testing whether remission can be maintained with a less intensive therapy approach
This work contributes to improving cancer care for younger patients while balancing effectiveness and long-term treatment burden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 692 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 638 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 144 by active trials.
lock +143 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +81 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Rennes
lock Showing 1 of 531 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 692 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 37 | Unknown | 2014-03-24 | 2026-06-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.